A research team led by Prof. Claude Perreault, Université de Montréal, is announcing a major discovery in Genomics. This will generate a fundamental impact on the treatment of blood cancers (leukemias and lymphomes) by means of peripheral blood T-cell grafts.

Gastrointestinal graft-vs.-host disease is a common and potentially deadly side effect for patients who undergo an allogeneic stem-cell transplant to treat certain blood cancers. Now, new research from Fred Hutchinson Cancer Research Center shows that adding a widely used topical corticosteroid to the standard treatment for GVHD kept the disease in remission and significantly reduces deaths one year after therapy.